Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award

The Ohio State University | United States

Dr. Ann-Kathrin Eisfeld is an internationally recognized physician-scientist and Associate Professor with Tenure in the Division of Hematology at The Ohio State University, where she also serves as Director of the Clara D. Bloomfield Center for Leukemia Outcomes Research. Her research focuses on the molecular and genetic underpinnings of acute myeloid leukemia (AML), with a particular emphasis on translational applications that improve patient outcomes. Dr. Eisfeld has published extensively in high-impact journals such as Nature, Leukemia, Blood, and Cell Stem Cell, contributing significantly to our understanding of leukemia biology, clonal evolution, and treatment resistance. she has authored over 100 peer-reviewed scientific publications, with an h-index of 38, more than 6,500 citations, and has led or co-led multiple collaborative studies within national consortia such as the Alliance for Clinical Trials in Oncology. Her work has identified critical biomarkers and therapeutic targets in AML, including insights into TP53 mutations, FLT3 alterations, and resistance mechanisms to venetoclax. Recognized for her integration of clinical insight with cutting-edge genomics, Dr. Eisfeld is a leading voice in precision oncology and leukemia research, shaping the future of individualized treatment strategies through both clinical innovation and scientific discovery.

Profile: Scopus

Featured Publications:

“Highly elevated serum hepcidin in patients with acute myeloid leukemia prior to and after allogeneic hematopoietic cell transplantation: Does this protect from excessive parenchymal iron loading?”

“Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia”

“miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia”

“Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia”

“Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation”

“inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations”

“Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients”

“In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline”

“A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia”

Saika Farook | Microbiology | Excellence in Research Award

Published on by Cell Biologist

Assist. Prof. Dr. Saika Farook | Microbiology | Excellence in Research Award

Assist. Prof. Dr. Saika Farook | Ibrahim Medical College | Bangladesh 

Dr. Saika Farook is a dedicated microbiologist from Bangladesh with a strong academic background and extensive experience in infectious diseases and microbiology. She earned her MD in Microbiology from BIRDEM Academy (BSMMU) and has been actively involved in research and teaching. Currently, she serves as an Assistant Professor at Ibrahim Medical College and an Adjunct Faculty at BRAC University. Dr. Farook’s work centers on identifying and combating bacterial infections, especially Burkholderia pseudomallei, the causative agent of melioidosis, a neglected tropical disease. She has contributed significantly to both clinical diagnostics and molecular research and has been recognized as a speaker at international conferences. Saika’s commitment to bridging laboratory findings with clinical practice makes her a valuable asset in the field of medical microbiology. She is a life member of Bangladesh Society of Medical Microbiologists and contributes globally to the American Society for Microbiology.

Publication Profile: 

Orcid
Scopus

Education:

Dr. Saika Farook completed her Bachelor of Medicine and Bachelor of Surgery (MBBS) from Noakhali Medical College, affiliated with Chittagong University. She then pursued a Doctor of Medicine (MD) in Microbiology from BIRDEM Academy under Bangabandhu Sheikh Mujib Medical University (BSMMU), graduating . Her early education includes O’ Levels from Shaheen English Medium School with 8 A’s and Higher Secondary Certificate (H.S.C.) from Rajuk Uttara Model College, Dhaka. Her rigorous academic journey demonstrates a consistent pursuit of excellence, culminating in advanced specialization in microbiology, infectious diseases, and molecular diagnostics. She has also enhanced her skills through multiple workshops on bioinformatics, bacterial genomics, and infection prevention.

Experience:

Dr. Farook has accumulated rich professional experience in both clinical and academic settings. She has been an Assistant Professor at Ibrahim Medical College’s Department of Microbiology. She holds an adjunct faculty role in the Department of Mathematics and Natural Science at BRAC University. Previously, she served as Junior Consultant at DMFR Molecular Lab & Diagnostics and worked as a Virologist during the critical COVID-19 period. She completed a rigorous MD residency in Microbiology at BIRDEM Academy and served as an intern doctor at Jananeta Nurul Haque Adhunik Hospital. Her roles highlight strong clinical acumen paired with research-driven teaching, enhancing laboratory diagnostic techniques and molecular microbiology.

Research Focus:

Dr. Saika Farook’s research primarily targets Burkholderia pseudomallei, the bacterium responsible for melioidosis, focusing on its detection, molecular epidemiology, and antimicrobial susceptibility. She has contributed to developing novel diagnostic methods, such as Loop Mediated Isothermal Amplification assays and selective culture media. Her research also explores the clinical epidemiology of infectious diseases, including latent tuberculosis and IgG4-related disorders. Funded by both Ibrahim Medical College and the Ministry of Health, her ongoing projects delve into molecular epidemiology and clinical sample analysis from tertiary hospitals in Dhaka. Her work bridges molecular diagnostics and public health, addressing gaps in disease recognition in Bangladesh. Dr. Farook has actively presented her findings in national and international forums, reflecting her commitment to advancing microbiological research with real-world clinical applications.

Publications Top Notes: 

  1. An improved Loop Mediated Isothermal Amplification based assay for the rapid Identification of Genomic DNA of Burkholderia pseudomallei

  2. Melioidosis cases detected in Dhaka, Bangladesh: a positive impact of 3rd South Asian Melioidosis Congress

  3. Effectiveness of a novel selective medium “Modified MacConkey Agar for Burkholderia” for isolation of Burkholderia pseudomallei

  4. Knowledge on melioidosis among healthcare workers of Bangladesh

  5. Melioidosis: Still Unresolved and Undetected in Unexplored Regions

  6. Interferon Gamma Release Assay for Latent Tuberculosis Screening in High TB-Endemic Region: A Retrospective Study

  7. Use of Comparative Genomics to resolve an unusual case of Aminoglycoside Susceptibility in Burkholderia pseudomallei

  8. Localized Disseminated Tuberculosis in a 3 year’s old Bangladeshi boy: A Case Study

  9. Modified MacConkey agar: a simple selective medium for isolation of Burkholderia pseudomallei from soil

  10.  Phylogeographic characterization of Burkholderia pseudomallei isolated from Bangladesh

Conclusion:

In conclusion, Dr. Saika Farook is a highly suitable candidate for the Research for Excellence in Research Award. Her strong academic background, significant research contributions in microbiology and infectious diseases, and active participation in academic and scientific communities demonstrate her dedication and impact in her field. With some strategic focus on expanding international collaborations, translational research, and leadership in mentoring, she could further strengthen her candidacy. Overall, her achievements and ongoing commitment to advancing medical microbiology make her an excellent contender for recognition through this award.

Alessandra Luchini | Microbial Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Alessandra Luchini | Microbial Cell Biology | Best Researcher Award

Dr. Alessandra Luchini , George Mason University , United States

Dr. Alessandra Luchini is a renowned professor at George Mason University, VA, and director of the Ph.D. program in Biosciences at the School of Systems Biology. With expertise in proteomics, nanotechnology, and bioengineering, she is committed to advancing diagnostics and therapeutics for diseases such as cancer, infections, and inflammatory diseases. Dr. Luchini holds a Ph.D. in Bioengineering from the University of Padova, Italy, and has contributed significantly to scientific research, publishing peer-reviewed papers and co-inventing multiple patents in nanotechnology and proteomics. As a co-founder of Ceres Nanosciences Inc. and Monet Pharmaceuticals, her work bridges academia and industry. Dr. Luchini’s innovations have earned her recognition, including being named one of the “Top 10 Brilliant Scientists” by Popular Science in 2011 and receiving the Outstanding Faculty Award in 2023 from the State Council of Higher Education for Virginia.

Publication Profile:

Orcid

Strengths for the Award:

Dr. Alessandra Luchini has a distinguished career, marked by her leadership at George Mason University, where she is both a tenured professor and the director of the Ph.D. Biosciences program. She is a key innovator in the areas of proteomics, nanotechnology, and bioengineering, contributing significantly to advancements in diagnostics and therapeutics for cancer, infectious, and inflammatory diseases. Notable strengths include:

  • Innovative Research: Dr. Luchini has developed groundbreaking technologies such as highly accurate proteomic diagnostic assays, and she is involved in drug resistance research for medulloblastoma. Her work on Borrelia peptides and bacteriophage therapy shows her ability to address complex issues in medicine.
  • Collaboration and Impact: She is co-founder of successful companies, Ceres Nanosciences and Monet Pharmaceuticals, and has been recognized as one of the top 10 most brilliant scientists by Popular Science in 2011.
  • Extensive Publication Record: With an H-index of 31, Dr. Luchini has published numerous influential articles and is highly cited in her field. Her innovative research crosses multiple disciplines, from nanotechnology to clinical diagnostics.
  • Patent Portfolio: She holds several patents for advancements in biomarker harvesting, immunoassays, and hydrogel particles, demonstrating her ability to translate research into practical applications.

Areas for Improvement:

While Dr. Luchini’s research has immense impact in both academic and practical settings, a potential area for improvement could involve expanding her work into more personalized medicine approaches. While she is already exploring diagnostics for specific diseases like medulloblastoma, further integration of genomics and individualized treatment plans could enhance her future work. Additionally, broadening her interdisciplinary collaborations to include non-traditional fields like AI-based diagnostics could further elevate her contributions.

Education:

Dr. Alessandra Luchini’s educational journey began at the University of Padova in Italy, where she earned a Bachelor’s degree in Chemical Engineering with honors in 2001. She continued her academic path by pursuing a Ph.D. in Bioengineering, completing the program in 2005. Dr. Luchini further enhanced her expertise through postgraduate training in Proteomics and Nanotechnology at George Mason University in 2007. Her academic training laid the foundation for her pioneering research in nanotechnology and proteomics, areas in which she has significantly contributed to both scientific publications and patent innovations. Her multidisciplinary approach combines engineering, biotechnology, and molecular medicine, making her a leading expert in the development of cutting-edge diagnostic tools and therapeutic strategies. Dr. Luchini’s work is instrumental in bridging scientific theory with real-world applications in healthcare.

Experience:

Dr. Alessandra Luchini has held significant roles at George Mason University, where she has been a professor in the School of Systems Biology since June 2020. In addition to her academic position, she has served as the Graduate Program Director for the Ph.D. program in Biosciences since January 2019. Prior to her tenure at George Mason, Dr. Luchini was involved in both academic research and industry, co-founding Ceres Nanosciences Inc. in 2008 and Monet Pharmaceuticals in 2019. Her work at these companies and within academia revolves around developing advanced diagnostic tools and therapeutics for a wide range of diseases, including cancer and infectious diseases. Dr. Luchini has authored numerous publications in peer-reviewed journals and holds several patents in the fields of nanotechnology and proteomics. Her innovative approach to healthcare solutions, blending academic research with practical applications, has made her an influential figure in the scientific community.

Awards and Honors:

Dr. Alessandra Luchini has earned several prestigious awards throughout her career, highlighting her remarkable contributions to science and technology. In 2011, she was named one of Popular Science‘s “Top 10 Most Brilliant Scientists,” a recognition that speaks to her significant impact in nanotechnology and proteomics. In 2023, Dr. Luchini was awarded the State Council of Higher Education for Virginia’s Outstanding Faculty Award, which acknowledged her exceptional work in education and research. Her achievements also include co-founding two innovative companies—Ceres Nanosciences Inc. and Monet Pharmaceuticals—which have developed cutting-edge diagnostic tools. In addition to these accolades, Dr. Luchini has received multiple research grants and honors for her work in biosciences, reinforcing her position as a leading expert in proteomics and nanotechnology. Her numerous awards underscore her leadership and transformative influence in the fields of molecular medicine and biotechnology.

Research Focus:

Dr. Alessandra Luchini’s research focuses on developing novel technologies for diagnostics and therapeutics in cancer, infectious, and inflammatory diseases. A key area of her work is the application of proteomics and nanotechnology to improve the detection and treatment of these conditions. She aims to create highly accurate diagnostic assays, including point-of-care devices that can be used to identify active infections like borreliosis. Another significant part of her research is tackling drug resistance in cancers like medulloblastoma, where she investigates the interaction of BAG-containing protein complexes to identify potential therapeutic targets. Additionally, Dr. Luchini’s research spans the development of nanotechnology-based diagnostic systems, such as the use of smart hydrogel particles and nanoparticle-enhanced immunoassays. Her work has substantial real-world applications, bridging the gap between cutting-edge science and practical healthcare solutions, with the goal of improving patient outcomes across a range of diseases.

Publications Top Notes:

  1. Urinary bacteriophage cooperation with bacterial pathogens during human urinary tract infections supports lysogenic phage therapy 🔬🦠 (Commun Biol, 2025)
  2. Urinary Borrelia Peptides Correlate with the General Symptom Questionnaire (GSQ30) Scores in Symptomatic Patients with Suspicion of Tick-borne Illness 🦠💡 (J Cell Immunol, 2025)
  3. Hearing Science Accelerator: Sudden Sensorineural Hearing Loss-Executive Summary of Research Initiatives 🧠🔊 (Otol Neurotol, 2024)
  4. A set of diagnostic tests for detection of active Babesia duncani infection 🧬🦠 (Int J Infect Dis, 2024)
  5. Protein Painting Mass Spectrometry in the Discovery of Interaction Sites within the Acetylcholine Binding Protein 🔬💉 (ACS Chem Neurosci, 2024)
  6. Wheat-Based Glues in Conservation and Cultural Heritage: (Dis)solving the Proteome of Flour and Starch Pastes and Their Adhering Properties 🏛️🧬 (J Proteome Res, 2024)
  7. Identification of Unambiguous Borrelia Peptides in Human Urine Using Affinity Capture and Mass Spectrometry 🔬💧 (Methods Mol Biol, 2024)
  8. Molecular and functional profiling of chemotolerant cells unveils nucleoside metabolism-dependent vulnerabilities in medulloblastoma 🧠⚡ (Acta Neuropathol Commun, 2023)
  9. Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling 🧬💉 (J Biol Chem, 2023)
  10. Drug discovery efforts at George Mason University 💊🧠 (SLAS Discov, 2023)

Conclusion:

Dr. Alessandra Luchini is an exceptional candidate for the Best Researcher Award, given her remarkable achievements in advancing scientific knowledge, developing life-saving technologies, and establishing successful enterprises. Her innovative work continues to shape the future of diagnostics and therapeutics, making her highly deserving of such an honor.